Amgen Inc. — Form 10-Q Summary
Business context and reporting period
Amgen is a global biotechnology company operating in one segment, human therapeutics. This unaudited filing covers the three months ended March 31, 2014, compared with the same period in 2013. Results include Onyx, acquired in October 2013; interim results are not necessarily indicative of full-year results.
Financial performance and liquidity
| Metric | Q1 2014 | Q1 2013 | Change |
|---|---|---|---|
| Total revenue | $4.521 billion | $4.238 billion | +7% |
| Product sales | $4.356 billion | $4.151 billion | +5% |
| Operating income | $1.364 billion | $1.442 billion | -5% |
| Net income | $1.073 billion | $1.434 billion | -25% |
| Diluted EPS | $1.40 | $1.88 | -26% |
| Operating cash flow | $1.142 billion | $1.049 billion | +$93 million |
- Revenue growth reflected Kyprolis and Onyx collaboration revenues, and stronger XGEVA, Prolia and Neulasta sales. U.S. product sales rose 4%; rest-of-world sales rose 9%.
- Cost of sales was 25.0% of product sales versus 17.9%; R&D was 23.6% versus 21.2%; SG&A was 23.5% versus 27.9%. Operating margin was approximately 30.2%, compared with 34.0%.
- Higher amortization and a $99 million Roche supply-contract termination charge contributed to higher cost of sales. R&D increased, particularly for later-stage and Onyx programs; SG&A decreased mainly after the ENBREL profit share expired.
- Cash and cash equivalents were $3.687 billion and marketable securities were $16.115 billion at March 31. Total debt was $32.024 billion, including $2.505 billion current; restricted investments were $3.414 billion. Stockholders’ equity was $22.741 billion.
- Cash from operations was $1.142 billion; investing activities used $765 million and financing activities used $495 million. Cash ended the quarter at $3.687 billion.
Material changes and developments
- Key product performance was mixed: XGEVA sales rose 25%, Prolia 38%, and EPOGEN 6%; ENBREL fell 5%, Aranesp 2%, and NEUPOGEN 3%. U.S. NEUPOGEN faced competition following expiration of material patents in December 2013.
- The effective tax rate was 10.9%, versus a tax benefit rate of 6.8% in Q1 2013. The prior-year comparison included a $185 million tax benefit from settlement of federal tax examinations and approximately $60 million from the reinstated R&D tax credit.
- Amgen paid $460 million in dividends and repaid $125 million of term-loan principal. No shares were repurchased in the quarter; $1.6 billion remained authorized.
Outlook, risks and unusual items
- Management estimated 2014 capital spending of approximately $800 million and said existing funds, operating cash flow and financing access should meet foreseeable needs. It did not plan significant share repurchases in 2014 or 2015. No numerical revenue or EPS guidance is provided in the filing text.
- Approximately $20.1 billion of cash, cash equivalents, marketable securities and restricted investments was generated in foreign tax jurisdictions and intended to remain invested abroad; repatriation could incur additional U.S. taxes.
- Management cited collection risk in Southern Europe: receivables in Spain, Italy, Greece and Portugal totaled $334 million, of which $206 million was past due. No significant losses had been incurred to date.
- Roche’s U.S. launch of MIRCERA was permitted from mid-2014 under a limited license; Amgen also cited potential future impact from competition for NEUPOGEN and Neulasta. The principal U.S. pegfilgrastim patent expires in 2015.
- In April 2014, Amgen reported that talimogene laherparepvec met the durable response-rate endpoint in a melanoma trial but did not meet the secondary overall-survival endpoint; the company was reviewing results. Related IPR&D and contingent consideration were $675 million and $334 million, respectively, at quarter-end.
- An April 1, 2014 agreement with Glaxo ended denosumab commercialization collaboration in most covered territories, with transition back to Amgen by December 31, 2014 and payments to Glaxo totaling $275 million. Australia remains under the collaboration.
- Amgen described ongoing legal proceedings, including Onyx shareholder litigation and an amended securities class-action complaint. The company said possible losses could not be estimated clearly; an adverse outcome in one or more matters could materially affect results, financial position or cash flows.
- The March evolocumab Phase 3 TESLA trial met its primary LDL-C reduction endpoint. The filing provides no quantified financial outlook beyond the capital-spending estimate and stated capital-allocation intentions.
Important facts for investors to verify
- Whether sales momentum in growth products can offset declines and competitive pressure in established products.
- The recurring earnings effect of Onyx-related amortization, acquired-product costs, and the comparison against unusually favorable Q1 2013 tax items.
- Debt maturities, refinancing and repayment capacity, alongside the substantial overseas-held liquidity balance and potential tax costs of repatriation.
- Clinical, regulatory and commercial prospects for talimogene laherparepvec and other pipeline assets, including the implications of the missed overall-survival endpoint.
- Progress of Glaxo territory transitions, European receivable collections, and material legal proceedings.